News, reviews and podcasts from annual scientific meetings and symposiums around the world.
ESMO 2O23: Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50 percent
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV…